Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy

References

• Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410–2411
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8
   PubMed Web of Science ®Google Scholar
• Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556–1563
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454
   PubMed Web of Science ®Google Scholar
• Tang PA, Vickers MM, Heng DY. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am 2011;25:871–891
   PubMed Web of Science ®Google Scholar
• Muselaers CH, Boerman OC, Oosterwijk E, et al. Indium-111-labeled Girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101--1106
   PubMed Web of Science ®Google Scholar
• Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010;58:75–83
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802–811
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007;25:4757–4764
   PubMed Web of Science ®Google Scholar
• Michael A, Pandha HS. Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4:215–223
   PubMed Web of Science ®Google Scholar
• Sandlund J, Oosterwijk E, Grankvist K, et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007;100:556–560
   PubMed Web of Science ®Google Scholar
• de Martino M, Klatte T, Seligson DB, et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol 2009;182:728–734
   PubMed Web of Science ®Google Scholar
• Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714–3721
   PubMed Web of Science ®Google Scholar
• McDermott DF. The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2010;28:15s (suppl:abstract 4514)
   Google Scholar
• Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 2010;106:772–778
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Cheng S, Qu AQ, et al. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol Oncol 2012;12:S1078--1439
   Google Scholar
• Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, et al. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother 2007;30:116–122
   PubMed Web of Science ®Google Scholar
• Monoclonal Antibody Therapy (Rencarex®) in Treating patients who have undergone surgery for nonmetastatic kidney cancer (NCT00087022). ClinicalTrials.gov: 2013
   Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997–2004
   PubMed Web of Science ®Google Scholar
• Donskov F. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Dan Med Bull 2007;54:249–265
   PubMed Web of Science ®Google Scholar
• Wang M, Tang ST, Stryhn A, et al. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. Immunology 2011;132:482–491
   PubMed Web of Science ®Google Scholar
• Harndahl M, Justesen S, Lamberth K, et al. Peptide binding to HLA class I molecules: homogenous, high throughput screening, and affinity assays. J Biomol Screen 2009;14:173–180
   PubMed Web of Science ®Google Scholar
• Harndahl M, Rasmussen M, Røder G, Buus S. Real-time, High throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods 2011;374:5--12
   Google Scholar
• Wang M, Lamberth K, Harndahl M, et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 2007;25:2823–2831
   PubMed Web of Science ®Google Scholar
• Mukouyama H, Janzen NK, Hernandez JM, et al. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res 2004;10:1421–1429
   PubMed Web of Science ®Google Scholar
• Vissers JL, de Vries IJ, Engelen LP, et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 2002;100:441–444
   PubMed Web of Science ®Google Scholar
• Vissers JL, de Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554–5559
   PubMed Web of Science ®Google Scholar
• Schmitt A, Barth TF, Beyer E, et al. The tumor antigens RHAMM and G250/CAIX are expressed in head and neck squamous cell carcinomas and elicit specific CD8+ T cell responses. Int J Oncol 2009;34:629–639
   PubMed Web of Science ®Google Scholar
• Uemura H, Fujimoto K, Tanaka M, et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res 2006;12:1768–1775
   PubMed Web of Science ®Google Scholar
• Claesson MH. Why current peptide-based cancer vaccines fail: lessons from the three Es. Immunotherapy 2009;1:513–516
   PubMed Web of Science ®Google Scholar
• Seta N, Kobayashi S, Hashimoto H, Kuwana M. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals. Clin Exp Rheumatol 2009;27:826–829
   PubMed Web of Science ®Google Scholar
• Oling V, Marttila J, Ilonen J, et al. GAD65- and proinsulin-specific CD4+ T cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005;25:235–243
   Google Scholar
• Pedersen AE, Stryhn A, Justesen S, et al. Wildtype p53 specific antibody and T cell responses in cancer patients. J Immunotherapy 2011;34:629--640
   Google Scholar
• Wang L, Wu XP, Zhang W, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One 2011;6:e17608
   Web of Science ®Google Scholar
• Kuniholm MH, Gao X, Xue X, et al. The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women. J Infect Dis 2011;203:1807–1814
   PubMed Web of Science ®Google Scholar
• Madeleine MM, Johnson LG, Smith AG, et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res 2008;68:3532–3539
   PubMed Web of Science ®Google Scholar
• Lamers CH, Sleijfer S, van SS, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013;21:904--912
   Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 2010;16:3255–3263
   PubMed Web of Science ®Google Scholar
• Zamai L, Ponti C, Mirandola P, et al. NK cells and cancer. J Immunol 2007;178:4011–4016
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Morita T, Augustus LB, von Eschenbach AC, Itoh K. Human renal-cell carcinoma cells are able to activate natural killer cells. Int J Cancer 1992;51:290–295
   PubMed Web of Science ®Google Scholar
• Donskov F, Bennedsgaard KM, von der MH, et al. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 2002;87:194–201
   PubMed Web of Science ®Google Scholar